SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other
about
The detection, treatment, and biology of epithelial ovarian cancerHE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseasesSerum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cystsIdentification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancerUse of a single-chain antibody library for ovarian cancer biomarker discovery.CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: implications for targeted gene therapy.Ovarian cancer biomarkers for molecular biosensors and translational medicine.HE4 in the differential diagnosis of a pelvic mass: a case report.HE4 as a biomarker for ovarian and endometrial cancer management.Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.Potential markers for detection and monitoring of ovarian cancer.Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in miceThe Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future OpportunitiesThe human epididymis protein 4 acts as a prognostic factor and promotes progression of gastric cancerIdentification of epithelial ovarian tumor-specific aptamers.Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates.Autoantibodies to mesothelin in infertility.The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancerEarly detection biomarkers for ovarian cancer.HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell LinesSerum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4.Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer.Anti-HE4 antibodies in infertile women and women with ovarian cancer.Investigating the clinical potential for 14-3-3 zeta protein to serve as a biomarker for epithelial ovarian cancer.HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival.Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis.Peri- and post-menopausal incidental adnexal masses and the risk of sporadic ovarian malignancy: new insights and clinical management.Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer.Does HE4 have a role as biomarker in the recurrence of ovarian cancer?Diagnostic and prognostic value of serum human epididymis protein 4 in patients with primary fallopian tube carcinoma.Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer.
P2860
Q21198791-A2C61B72-44C9-4F28-8D93-7152539598E5Q24634978-2DBE8B2E-EAB3-49A3-BB5E-AF8C6EF62F27Q24651331-84CCD92A-0D73-4F1E-9908-A0DEE55CDEE4Q28478197-436C2483-BE19-4985-B63C-D4CDB2875DA8Q33577786-FF130083-375B-4CE3-B5C8-C2A7B0DA489AQ34134506-85C9B1EA-4874-4466-83D8-EA05A8F7B998Q34150097-66515038-28CD-4A3A-8040-82ABFC91A3F9Q34578148-E11FFCEC-605D-4ABF-97ED-6CD7F955C140Q34611530-9C1E883F-7B47-44E6-B784-EF3FBFFA4A5AQ34738849-43BD715A-48E3-4522-AEDA-AF8419799C27Q34960174-7865A3C5-172B-429F-91C6-A88300DBE0B3Q34994831-33D74222-AAA6-4D29-8EC0-757D89EB50F5Q35185640-1E7ADB17-1AF1-4B60-ABCC-E3F26D36F062Q35596885-FA688B95-ED2F-417A-A192-958B9F7F7F79Q35635298-D0BE71E3-6E0C-4B2A-A51C-F79D5AAC5009Q35661217-BA5C1238-8427-4161-8032-0DDC672814B3Q35832948-14AE9789-9C90-4DD1-AACB-439D64E5535FQ35976828-1F4B52D4-667B-454E-AD10-FF8D17B783DAQ36346403-9A1AD92F-51AE-4268-9D9A-AF4246344AC6Q36520143-5D2AB174-3883-4BFC-9558-2D7A4C0FD7BCQ36790307-7549292D-3442-4C90-AB12-CFB182BE2D0CQ36808757-8FC3C1D7-4D89-4FAE-9A35-868347593972Q36954678-C55B82FD-DE48-4A71-86B0-0F5CDD22741EQ37107033-39647A3F-27C8-4716-87CE-8D8991CB428DQ37329737-747468FF-1964-485F-B2BF-D829E8142050Q37375504-81ADF12C-4699-4FD7-A45A-BB9496617EAEQ37383509-1B9A5A23-3BF0-4CE5-87F9-78D701F280C7Q37553857-A327C56D-55FF-4316-B389-522B8F943F99Q37706040-BDA5E05C-1A34-452B-B4E5-53BA6FBC107CQ37760524-944282E1-E345-4EC4-9D78-A5262B744496Q37967486-B15EB126-5107-4C15-8689-774A212C3982Q43799326-B71791F8-44B9-4789-A875-40F14E1F8C3CQ50921075-C8C74CCD-81E8-4190-B5A0-03BB8ECD459AQ51701060-6262C6B6-F375-429E-9719-01504BBB056BQ53411263-D8631116-5039-4379-864D-3E9E0C183F65
P2860
SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
SMRP and HE4 as biomarkers for ...... n with CA125 and/or each other
@ast
SMRP and HE4 as biomarkers for ...... n with CA125 and/or each other
@en
SMRP and HE4 as biomarkers for ...... n with CA125 and/or each other
@nl
type
label
SMRP and HE4 as biomarkers for ...... n with CA125 and/or each other
@ast
SMRP and HE4 as biomarkers for ...... n with CA125 and/or each other
@en
SMRP and HE4 as biomarkers for ...... n with CA125 and/or each other
@nl
prefLabel
SMRP and HE4 as biomarkers for ...... n with CA125 and/or each other
@ast
SMRP and HE4 as biomarkers for ...... n with CA125 and/or each other
@en
SMRP and HE4 as biomarkers for ...... n with CA125 and/or each other
@nl
P3181
P1476
SMRP and HE4 as biomarkers for ...... n with CA125 and/or each other
@en
P2093
Ingegerd Hellstrom
Karl Erik Hellstrom
P3181
P356
10.1007/978-0-387-68969-2_2
P407
P577
2008-01-01T00:00:00Z